Exendin-4 for Parkinson's disease

This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Esparza-Salazar, Felipe de Jesús, Lezama-Toledo, Alma Rosa, Rivera-Monroy, Germán, Borlongan, Cesario V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057099/
https://www.ncbi.nlm.nih.gov/pubmed/34084977
http://dx.doi.org/10.4103/bc.bc_21_21
_version_ 1783680773020188672
author Esparza-Salazar, Felipe de Jesús
Lezama-Toledo, Alma Rosa
Rivera-Monroy, Germán
Borlongan, Cesario V.
author_facet Esparza-Salazar, Felipe de Jesús
Lezama-Toledo, Alma Rosa
Rivera-Monroy, Germán
Borlongan, Cesario V.
author_sort Esparza-Salazar, Felipe de Jesús
collection PubMed
description This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.
format Online
Article
Text
id pubmed-8057099
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-80570992021-06-02 Exendin-4 for Parkinson's disease Esparza-Salazar, Felipe de Jesús Lezama-Toledo, Alma Rosa Rivera-Monroy, Germán Borlongan, Cesario V. Brain Circ Review Article This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD. Wolters Kluwer - Medknow 2021-03-30 /pmc/articles/PMC8057099/ /pubmed/34084977 http://dx.doi.org/10.4103/bc.bc_21_21 Text en Copyright: © 2021 Brain Circulation https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Esparza-Salazar, Felipe de Jesús
Lezama-Toledo, Alma Rosa
Rivera-Monroy, Germán
Borlongan, Cesario V.
Exendin-4 for Parkinson's disease
title Exendin-4 for Parkinson's disease
title_full Exendin-4 for Parkinson's disease
title_fullStr Exendin-4 for Parkinson's disease
title_full_unstemmed Exendin-4 for Parkinson's disease
title_short Exendin-4 for Parkinson's disease
title_sort exendin-4 for parkinson's disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057099/
https://www.ncbi.nlm.nih.gov/pubmed/34084977
http://dx.doi.org/10.4103/bc.bc_21_21
work_keys_str_mv AT esparzasalazarfelipedejesus exendin4forparkinsonsdisease
AT lezamatoledoalmarosa exendin4forparkinsonsdisease
AT riveramonroygerman exendin4forparkinsonsdisease
AT borlongancesariov exendin4forparkinsonsdisease

Ejemplares similares